Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022. The report details a specific corporate action regarding the transfer of treasury shares to facilitate employee compensation plans.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements and transaction pricing related to treasury shares.
- Treasury Shares Transferred: 50,300,000 ordinary shares.
- Transaction Price (Jersey Trust): £16.208 per Ordinary Share.
- Transaction Price (US Trust/ADR): $44.260 per ADR (representing $22.130 per Ordinary Share).
- Issued Share Capital (as of Feb 11, 2022): 5,388,496,258 Ordinary Shares.
- Treasury Shares Held (as of Feb 11, 2022): 304,905,950 Ordinary Shares.
- Total Voting Rights: 5,083,590,308.
Material Changes
On February 10, 2022, GSK transferred 50,300,000 ordinary shares from its treasury. These shares were allocated as follows:
- 34,500,000 shares transferred to the GlaxoSmithKline Employee Trust (Jersey Trust).
- 15,800,000 shares transferred to JPMorgan Chase Bank, N.A. to procure the issuance of 7,900,000 American Depositary Receipts (ADRs) for the GlaxoSmithKline (US) Trust.
These transfers were executed to satisfy awards under the Company's Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan. The consideration for the Jersey Trust transfer was funded by a loan from GlaxoSmithKline Services Unlimited, while the US Trust consideration was funded by a contribution from GlaxoSmithKline LLC.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural report of a share transfer.
Important Facts for Investors to Verify
- Verify the impact of the 50,300,000 share transfer on the total number of voting rights, which stands at 5,083,590,308.
- Confirm the funding sources for the share transfers: a loan from GlaxoSmithKline Services Unlimited for the Jersey Trust and a contribution from GlaxoSmithKline LLC for the US Trust.
- Note that the total issued share capital remains 5,388,496,258, with 304,905,950 shares remaining in treasury as of February 11, 2022.
- Understand that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly reports for revenue and earnings information.